Wong, Raymond
Fishman, Jesse
Wilson, Koo
Yeh, Michael
Al-Adhami, Mohammed
Zion, Abigail
Yee, Christopher W.
Huynh, Lynn http://orcid.org/0000-0003-3110-6775
Duh, Mei Sheng
Clinical trials referenced in this document:
Documents that mention this clinical trial
Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s12325-023-02438-9
Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan
https://doi.org/10.1007/s40268-024-00463-9
Funding for this research was provided by:
Apellis Pharmaceuticals
Article History
Received: 28 November 2022
Accepted: 17 January 2023
First Online: 7 February 2023
Change Date: 4 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-023-02640-9
Declarations
:
: Raymond Wong was an investigator on the PRINCE trial funded by Apellis Pharmaceuticals. Jesse Fishman, Michael Yeh, and Mohammed Al-Adhami are employees of Apellis Pharmaceuticals, Inc. and own stock/stock options. Koo Wilson is an employee of Sobi AB and holds company shares. Abigail Zion, Christopher W. Yee, Lynn Huynh, and Mei Sheng Duh are employees of Analysis Group Inc., which received research funding from Apellis Pharmaceuticals, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers of this manuscript have no relevant financial or other relationships to disclose.
: The two trials that were the basis of the analyses performed in this study were conducted in accordance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The study protocols were approved by the institutional review board or ethics committee at each study site, and all patients provided written informed consent.